Clinicopathological Characteristics of high and low-grade Ovarian Serous Carcinoma


  • Yemima Tangdiung Department of Anatomical Pathology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
  • Rina Masadah Department of Anatomical Pathology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
  • Berti Julian Nelwan Department of Anatomical Pathology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
  • Mahmud Ghaznawie Department of Anatomical Pathology, Faculty of Medicine, University of Muhammadiyah Makassar, Makassar, Indonesia.
  • Syarifuddin Wahid Department of Anatomical Pathology, Faculty of Medicine, Muslim University of Indonesia, Makassar, Indonesia.
  • Gita Vita Soraya Department of Biochemistry, Hasanuddin University, Makassar, Indonesia


serous carcinoma, ovary, characteristics, metastases


Ovarian cancer is the third most common gynecologic malignancy worldwide, after cervical cancer and endometrial cancer, but it has the highest mortality-to-incidence ratio of the three, indicating that it is fatal. Serous carcinoma is divided into two subtypes: low-grade serous carcinoma (LGSC) and high-grade serous carcinoma (HGSC). The purpose of this descriptive study is to determine the clinical characteristics of LGSC and HGSC patients based on five parameters: age, patient's chief complaint, tumor location, FIGO staging, and metastasis. For the period January 2017 to December 2021, 167 samples were collected based on histopathological data from three anatomical pathology laboratories in Makassar, consisting of 47 LGSC samples and 120 HGSC samples. The findings revealed that the most common age in LGSC and HGSC was 40-60 years (70.21% in LGSC and 70.83 percent in HGSC), and the most common chief complaint was abdominal enlargement (95.74% in LGSC and 94.17% in HGSC). LGSC is most commonly unilateral (53.20%), stage I-II (57.45%, and not metastatic (59.57%). In HGSC, it was most commonly bilateral (55%), 82 (68.33%) were diagnosed at stage III-IV, and most had metastases to the omentum (62.50%). In both types of tumors, the omentum is the most common site of tumor metastasis.

Keyword : serous carcinoma, ovary, characteristics, metastasis


. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: Epidemiology and risk factors. Int J Womens Health. 2019;11:287–99.

. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I BF. Ovarian Cancer Incidence and Mortality. Int Agency Res Cancer GLOBOCAN [Internet]. 2020;5–6. Available from:

. WHO. Cancer Insiden in Indonesia. 2020;858:1–2.

. Kurman RJ, Shih IM. The dualistic model of ovarian carcinogenesis revisited, revised, and expanded. Am J Pathol [Internet]. 2016;186(4):733–47. Available from:

. Kroeger PT, Drapkin R. Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol. 2017;29(1):26–34.

. Zhang XY, Zhang PY. Recent perspectives of epithelial ovarian carcinoma (Review). Oncol Lett. 2016;12(5):3055–8.

. Kurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer - Shifting the paradigm. Hum Pathol [Internet]. 2011;42(7):918–31. Available from:

. Koshiyama M, Matsumura N, Konishi I. Recent concepts of ovarian carcinogenesis: Type i and type II. Biomed Res Int. 2014;2014.

. WHO Classification of Tumours Editorial Board. Female Genital Tumours : WHO Classification of Tumours. 5th ed. Lyon, France: IARC; 2020.

. Okoye E, Euscher ED, Malpica A. Ovarian Low-grade Serous Carcinoma at a Single Institution. 2016;00(00):1–9.

. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284–96.

. T.A. Longacre MW. Tumours of The Ovary. In: WHO Classification of Tumours of Female Reproductive Organs. 2014. p. 11–24.

. Serous H, Features B, Problems D. NIH Public Access. 2010;16(5):267–82.

. Ahn G, Folkins AK, McKenney JK, Longacre TA. Low-grade Serous Carcinoma of the Ovary: Clinicopathologic Analysis of 52 Invasive Cases and Identification of a Possible Noninvasive Intermediate Lesion. Am J Surg Pathol. 2016;40(9):1165–76.

. Li Y, Lu S, Xu Y, Qiu C, Jin C, Wang Y, et al. Overexpression of CD47 predicts poor prognosis and promotes cancer cell invasion in high-grade serous ovarian carcinoma. Am J Transl Res. 2017;9(6):2901–10.

. Kumar Abbas Aster. Robbins Basic pathology, 9th Edition. Elsevier Saunders. 2013.

. D.S. T, R. A, S.B. K. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol [Internet]. 2006;7(11):925–34. Available from:

. Kaldawy A, Segev Y, Lavie O, Auslender R, Sopik V, Narod SA. Low-grade serous ovarian cancer: A review. Gynecol Oncol [Internet]. 2016;143(2):433–8. Available from:

. Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M, et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun [Internet]. 2017;8(1):1–10. Available from:

. Eugenia C. Colon JWC. Serous Neoplasm of The Ovary. In: Pathology of the Ovary, Fallopian Tube and Peritoneum. 2014. p. 209–24.




How to Cite

Yemima Tangdiung, Masadah, R., Berti Julian Nelwan, Mahmud Ghaznawie, Syarifuddin Wahid, & Gita Vita Soraya. (2022). Clinicopathological Characteristics of high and low-grade Ovarian Serous Carcinoma. International Journal of Sciences: Basic and Applied Research (IJSBAR), 62(1), 275–280. Retrieved from